

North America


Treatment at diagnosis by country

Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




Treatment at diagnosis by country



Treatment at diagnosis by region



Treatment at diagnosis by cohort



Baseline characteristics

		North America N=(1618)	World N=(52081)
Sex	Female, n (%)	734 (45.4)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	71.2 (11.9)	69.7 (11.5)
Age Group	<65, n (%)	441 (27.3)	15716 (30.2)
	65-74, n (%)	492 (30.4)	16956 (32.6)
	>=75, n (%)	685 (42.3)	19409 (37.3)
BMI (kg/m ²)	mean (sd)	30.3 (7.3)	27.8 (5.7)
Pulse (bpm)	mean (sd)	95.8 (30.4)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	131.7 (21.3)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	78.0 (14.7)	79.7 (12.9)
Congestive heart failure	n (%)	248 (15.3)	10405 (20.0)
Coronary artery disease	n (%)	386 (23.9)	11251 (21.6)
Acute coronary syndrome	n (%)	187 (11.6)	4914 (9.5)
Carotid Occlusive Disease	n (%)	56 (3.5)	1546 (3.0)
Cirrhosis	n (%)	14 (0.9)	296 (0.6)

Baseline characteristics

		North America N=(1618)	World N=(52081)
Diabetes	n (%)	425 (26.3)	11550 (22.2)
History of Bleeding	n (%)	77 (4.8)	1320 (2.5)
Hypercholesterolaemia	n (%)	938 (59.1)	20975 (41.6)
PE or DVT	n (%)	73 (4.6)	1356 (2.6)
Stroke/TIA	n (%)	177 (10.9)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	441 (31.8)	12547 (28.5)
	In the public sector, n (%)	945 (68.2)	31431 (71.5)

Baseline characteristics

		North America N=(1618)	World N=(52081)
CHADS2 Score	mean (sd)	1.9 (1.2)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	3.3 (1.6)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.6 (0.9)	1.4 (0.9)

Baseline characteristics

		North America N=(1618)	World N=(52081)
Systemic Embolization	n (%)	10 (0.6)	336 (0.6)
Type of AF Diagnosed	New, n (%)	1139 (70.4)	23366 (44.9)
	Paroxysmal, n (%)	343 (21.2)	14313 (27.5)
	Permanent, n (%)	36 (2.2)	6639 (12.7)
	Persistent, n (%)	100 (6.2)	7761 (14.9)
Care Setting Speciality at Diagnosis	Cardiology, n (%)	967 (59.8)	34219 (65.7)
	Geriatrics, n (%)	1 (0.1)	202 (0.4)
	Internal Medicine, n (%)	336 (20.8)	9372 (18.0)
	Neurology, n (%)	10 (0.6)	876 (1.7)
	Primary Care/General Practice, n (%)	304 (18.8)	7410 (14.2)


Main reason anticoagulant not used for patients with CHA₂DS₂-VASc ≥2 .

	Cohort 1&2			
	North America		World	
	(N=83)		(N=4137)	
	n	%	n	%
Patients with CHA ₂ DS ₂ -VASc ≥2 and no AC treatment at diagnosis				
Alcohol abuse	1	(1.2)	20	(0.5)
Already taking anti-platelet drugs for other medical condition	4	(4.8)	228	(5.5)
Patient refusal	3	(3.6)	336	(8.1)
Previous bleeding event	3	(3.6)	63	(1.5)
Taking medication contraindicated or cautioned for use with VKA or AC			19	(0.5)
Other	41	(49.4)	505	(12.2)
Unknown	13	(15.7)	889	(21.5)
Physician's choice	18	(21.7)	2077	(50.2)
Physician's choice - Bleeding risk	4	(4.8)	263	(6.4)
Physician's choice - Concern over patient compliance	1	(1.2)	182	(4.4)
Physician's choice - Guideline recommendation	2	(2.4)	105	(2.5)
Physician's choice - Fall risk	3	(3.6)	197	(4.8)
Physician's choice - Low risk of stroke	2	(2.4)	326	(7.9)
Physician's choice - Other	6	(7.2)	1004	(24.3)
Total	83	(100.0)	4137	(100.0)


Main reason anticoagulant not used for patients with CHA₂DS₂-VASc ≥2.

	Cohort 3&4&5			
	North America		World	
	(N=246)		(N=6117)	
	n	%	n	%
Patients with CHA ₂ DS ₂ -VASc ≥2 and no AC treatment at diagnosis				
Alcohol abuse	1	(0.4)	32	(0.5)
Already taking anti-platelet drugs for other medical condition	6	(2.4)	422	(6.9)
Patient refusal	15	(6.1)	645	(10.5)
Previous bleeding event	7	(2.8)	151	(2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	4	(1.6)	63	(1.0)
Other	80	(32.5)	1326	(21.7)
Unknown	71	(28.9)	1597	(26.1)
Physician's choice	62	(25.2)	1881	(30.8)
Physician's choice - Bleeding risk	17	(6.9)	611	(10.0)
Physician's choice - Concern over patient compliance	2	(0.8)	248	(4.1)
Physician's choice - Guideline recommendation	10	(4.1)	189	(3.1)
Physician's choice - Fall risk	7	(2.8)	205	(3.4)
Physician's choice - Low risk of stroke	26	(10.6)	628	(10.3)
Total	246	(100.0)	6117	(100.0)


Stroke risk profile: CHADS₂



Stroke risk profile: CHA₂DS₂ VASc



Stroke risk profile: HAS BLED




Treatment at diagnosis by CHA₂DS₂-VASc score - North America

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
North America	Unknown	14	8	2	4	6	1	35
	0	5	18	4	10	11	0	48
	1	14	67	13	48	34	0	176
	2	30	126	21	63	45	6	291
	3	96	131	25	64	49	3	368
	4	95	148	24	65	35	6	373
	5	61	65	12	30	21	6	195
	6-9	46	46	4	18	18	0	132


Treatment at diagnosis by CHA₂DS₂-VASc score - World

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887

Treatment at diagnosis



Treatment at diagnosis




Treatment at diagnosis by HAS BLED score - North America

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
North America	Unknown	135	162	33	87	77	5	499	499
	0	18	60	10	0	30	1	119	119
	1	52	185	33	50	64	7	391	391
	2	97	168	25	116	36	7	449	449
	3	47	29	3	44	10	1	134	134
	4-9	12	5	1	5	2	1	26	26


Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

Treatment at diagnosis



Treatment at diagnosis



INR values and time in therapeutic range

Variable	Statistics	North America (N = 361) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	4968 (105)	157134 (8319)
	<2	1626 (32.7)	50514 (32.1)
	2-3	2538 (51.1)	81056 (51.6)
	>3	804 (16.2)	25564 (16.3)
INR value	n (missing)	4968 (105)	157134 (8319)
	Mean (SD)	2.4 (0.9)	2.4 (0.9)
	Median (IQR)	2.2 (1.8 to 2.7)	2.3 (1.8 to 2.8)
	Min to Max	0.8 to 18.9	0.8 to 20.0
TTR, n(%)	n (missing)	256 (105)	11485 (8720)
	<65	144 (56.3)	6734 (58.6)
	>=65	112 (43.8)	4751 (41.4)
TTR	n (missing)	256 (105)	11485 (8720)
	Mean (SD)	58.8 (24.6)	55.2 (27.3)
	Median (IQR)	62.8 (43.5 to 76.8)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

Event rates during the first year of follow-up (rates per 100 person-years)

	North America		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	91	6.19 (5.04 to 7.60)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	20	1.36 (0.88 to 2.11)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	38	2.58 (1.88 to 3.55)	771	1.61 (1.50 to 1.72)
Undetermined Cause	33	2.24 (1.60 to 3.16)	543	1.13 (1.04 to 1.23)
Stroke/SE	19	1.30 (0.83 to 2.04)	650	1.36 (1.26 to 1.47)
Major Bleeding	29	1.99 (1.38 to 2.86)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	14	0.95 (0.56 to 1.61)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	56	3.89 (3.00 to 5.06)	1052	2.22 (2.09 to 2.35)

Cause of death during the first year of follow-up

	North America		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	10	50.0	262	33.2
Sudden or unwitnessed death	2	10.0	127	16.1
Myocardial infarction	2	10.0	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	0		86	10.9
Non Cardiovascular causes				
Malignancy	13	34.2	233	30.2
Respiratory failure	11	28.9	142	18.4
Infection	3	7.9	81	10.5
Sepsis	2	5.3	74	9.6

Type of stroke during the first year of follow-up

	North America		World	
	n	%	n	%
Stroke (not including systemic embolism)	16	0.99	585	1.12
Primary Ischemic	9	0.56	406	0.78
of which secondary hemorrhagic ischemic			22	0.04
Primary intracerebral hemorrhage	4	0.25	71	0.14
Intracerebral	4	0.25	44	0.08
Intraventricular	1	0.06	9	0.02
Subarachnoid	1	0.06	13	0.02
Undetermined	3	0.19	108	0.21

Severity of bleeding during the first year of follow-up

Outcome	North America		World	
	n	%	n	%
Major Bleed	29	0.06	407	0.78
Non-Major Clinically Relevant	37	0.07	645	1.24
Minor	51	0.10	1167	2.24
Unknown	11	0.02	136	0.26